Literature DB >> 34291333

miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.

Marie-Christina Mayer1, Johannes Lorenz Berg1, Bianca Perfler1, Stefan Hatzl1, Sereina Annik Herzog2, Gerhard Bachmaier2, Andrea Berghold2, Andreas Reinisch1, Albert Wölfler1, Heinz Sill1, Armin Zebisch3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34291333     DOI： 10.1007/s00277-021-04598-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  9 in total

Review 1.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 2.  Myelodysplastic Syndromes.

Authors:  Mario Cazzola
Journal:  N Engl J Med       Date:  2020-10-01       Impact factor: 91.245

Review 3.  MicroRNAs in cancer.

Authors:  Gianpiero Di Leva; Michela Garofalo; Carlo M Croce
Journal:  Annu Rev Pathol       Date:  2013-09-25       Impact factor: 23.472

4.  Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2020-01       Impact factor: 10.047

Review 5.  MicroRNAs in myeloid malignancies.

Authors:  Jane E A Gordon; Justin J-L Wong; John E J Rasko
Journal:  Br J Haematol       Date:  2013-05-16       Impact factor: 6.998

6.  Acute myeloid leukemia with TP53 germ line mutations.

Authors:  Armin Zebisch; Ridhima Lal; Marian Müller; Karin Lind; Karl Kashofer; Michael Girschikofsky; David Fuchs; Albert Wölfler; Jochen B Geigl; Heinz Sill
Journal:  Blood       Date:  2016-09-12       Impact factor: 22.113

7.  Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis.

Authors:  Veronica Caraffini; Olivia Geiger; Angelika Rosenberger; Stefan Hatzl; Bianca Perfler; Johannes L Berg; Clarice Lim; Herbert Strobl; Karl Kashofer; Silvia Schauer; Christine Beham-Schmid; Gerald Hoefler; Klaus Geissler; Franz Quehenberger; Walter Kolch; Dimitris Athineos; Karen Blyth; Albert Wölfler; Heinz Sill; Armin Zebisch
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

8.  Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP.

Authors:  Stefan Hatzl; Olivia Geiger; Maja Kim Kuepper; Veronica Caraffini; Till Seime; Tobias Furlan; Erika Nussbaumer; Rotraud Wieser; Martin Pichler; Marcel Scheideler; Katarzyna Nowek; Mojca Jongen-Lavrencic; Franz Quehenberger; Albert Wölfler; Jakob Troppmair; Heinz Sill; Armin Zebisch
Journal:  Cancer Res       Date:  2016-04-15       Impact factor: 12.701

9.  Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Authors:  Karl Kashofer; Max Gornicec; Karin Lind; Veronica Caraffini; Silvia Schauer; Christine Beham-Schmid; Albert Wölfler; Gerald Hoefler; Heinz Sill; Armin Zebisch
Journal:  Leuk Lymphoma       Date:  2017-06-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.